©2024 Stanford Medicine
Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer
Not Recruiting
Trial ID: NCT00226954
Purpose
Primary:
To determine the duration of use of zoledronic acid in improving Bone mineral density in
patients with prostate cancer who are on hormones intermittently.
Secondary Objectives:
To describe the safety and tolerability at this dose and schedule
Official Title
Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer
Stanford Investigator(s)
Sandy Srinivas
Professor of Medicine (Oncology) and, by courtesy, of Urology
Eligibility
Inclusion Criteria:Patients: Who are 18 years of age and older Who have histologically
documented adenocarcinoma of prostate Who are currently receiving LHRH agonists KPS greater
than 80%Life expectancy greater than 6 months Provide written consent pursuant to
regulatory requirements prior to initiation of study procedure Exclusion Criteria:Exclusion
Criteria: Patients: Any patient requiring continuous LHRH Any patient who has had an
orchiectomy Any patient with painful bone metastases Who have received chemotherapy for
prostate cancer Who have a abnormal serum creatine >2.5 Receiving any investigational drug
within the last 28 days Severe uncontrolled infection, diabetes, cardiac disease Patients
with fragility fractures, hyperparathyroidism, Pagets renal osteodystrophy will be excluded
History of non compliance to medical regimens or unwillingness to return for medical visits
Intervention(s):
drug: zoledronic acid
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Denise Haas
6507361252